InsidersTradesSigma
Enzo Biochem INC Stock: price and insider trades · United States · SEC (Form 4)
Track the Enzo Biochem INC stock price and the full insider trade history of the company, a listed equity based in United States. Shares trade on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Enzo Biochem INC has recorded 36 insider filings. The latest transaction was reported on 17 January 2025 (Attribution). Among the most active insiders: Radoff Bradley Louis. Every trade is openly available.
36
Insider Decl.
0
Thresholds
€677,195
9 ops.
Buy Volume
·
0 ops.
Sell Volume
40Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 17 January 2025
Declarations36 total
142,897 shares0Common StockSEC:0001213900-25-004656:0
142,897 shares0Common StockSEC:0001213900-25-004655:0
142,897 shares0Common StockSEC:0001213900-25-004653:0
70,885 shares@ US$1.1792.7% of flowCommon StockSEC:0001013762-24-000834:0
10,640 shares0Common StockSEC:0001213900-24-017640:0
79,365 shares0Common StockSEC:0001213900-24-009795:0
79,365 shares0Common StockSEC:0001213900-24-009794:0
79,365 shares0Common StockSEC:0001213900-24-009793:0
17,730 shares0Common StockSEC:0001213900-23-096070:0
345,080 shares0Common Stock, $0.01 Par ValueSEC:0001213900-23-074085:0
75,188 shares0Common Stock, $0.01 Par ValueSEC:0001213900-23-010983:0
75,188 shares0Common Stock, $0.01 Par ValueSEC:0001213900-23-010982:0
5,000 shares@ US$1.291.1% of flowCommon Stock, $0.01 par valueSEC:0001290929-23-000008:0
Ideal exit: 7 Nov 2023 (T+270)
75,188 shares0Common Stock, $0.01 Par ValueSEC:0001213900-23-010986:0
12,600 sharesCommon Stock, $0.01 Par ValueSEC:0001213900-23-006418:0
11,800 shares@ US$1.402.8% of flowCommon Stock, $0.01 par valueSEC:0001290929-23-000007:0
Ideal exit: 24 Oct 2023 (T+270)
228,700 shares@ US$2.5096.0% of flowCommon Stock, $0.01 par valueSEC:0001290929-23-000006:0
300 shares@ US$2.500.1% of flowCommon Stock, $0.01 par valueSEC:0001290929-23-000005:0
100,000 shares@ US$1.9784.1% of flowCommon Stock, $0.01 Par ValueSEC:0001213900-22-075598:0
Ideal exit: 20 Aug 2023 (T+270)
2,500 shares@ US$2.427.3% of flowCommon Stock, $0.01 Par ValueSEC:0001213900-22-040369:0
Ideal exit: 11 Apr 2023 (T+270)
41,666 shares0Common Stock, $0.01 Par ValueSEC:0001213900-22-039467:0
41,666 shares0Common Stock, $0.01 Par ValueSEC:0001213900-22-039466:0
41,666 shares0Common Stock, $0.01 Par ValueSEC:0001213900-22-039468:0
12,500 shares@ US$2.275.4% of flowCommon Stock, $0.01 Par ValueSEC:0001213900-22-038978:0
Ideal exit: 8 Apr 2023 (T+270)
120,000 shares@ US$2.2049.2% of flowCommon Stock, $0.01 Par ValueSEC:0001213900-22-037633:0
Ideal exit: 1 Apr 2023 (T+270)
25 of 36 declarations
About Enzo Biochem INC
Enzo Biochem Inc. is a U.S.-based life sciences company with a long operating history and a niche position in research tools and diagnostics. It began operations in August 1976 and is headquartered in Farmingdale, New York, United States. From a market perspective, the company was long associated with the NYSE, but in 2025 it voluntarily delisted from the NYSE and moved its common stock trading to the OTCQX market under the symbol ENZB. For investors, that change is important because it reflects both the company’s small-cap profile and the evolution of its capital-markets access. ([ir.enzo.com](https://ir.enzo.com/company-information/faq?utm_source=openai)) Today, Enzo’s core business is conducted through Enzo Life Sciences. The company focuses on labeling and detection technologies spanning DNA-based applications through whole-cell analysis. Its portfolio includes antibodies, genomic probes, assays, biochemicals, and proteins, which are used in translational research, drug discovery, drug development, cell biology, genomics, immunohistochemistry, and related scientific workflows. Enzo also highlights a sizeable intellectual-property base and a large installed scientific reputation, with more than 500 patents and a long record of peer-reviewed citations supporting its product franchise. ([enzo.com](https://www.enzo.com/about-enzo/?utm_source=openai)) In competitive terms, Enzo operates in a specialized segment of the global life-science tools market. It competes with larger diversified suppliers, but its differentiation comes from a focused catalog, internally supported manufacturing and validation, and a product set that is tailored to researchers, biotech companies, pharma customers, and diagnostic users. The company describes its Long Island campus as a hub for research and development, manufacturing, customer service, and warehouse operations, while also serving a global market through distribution channels and product sales. ([enzo.com](https://www.enzo.com/about-enzo/locations/?utm_source=openai)) Recent headlines have been shaped by corporate simplification and risk management. In March 2025, Enzo announced its intent to delist from the NYSE; the last day of NYSE trading was April 17, 2025, and OTCQX trading began on April 21, 2025. In parallel, the company disclosed progress on a class-wide settlement related to the April 2023 cyber incident, with court approval granted in June 2025. On the operating side, management emphasized new product launches, stating that approximately 100 products were launched during the third quarter of fiscal 2025, while also noting continued headwinds in life-science tools, including weaker government grant activity, reduced R&D spending, and tariff-related uncertainty. ([ir.enzo.com](https://ir.enzo.com/news-events/press-releases/detail/342/enzo-biochem-reports-third-quarter-fiscal-year-2025-results?utm_source=openai)) Overall, Enzo Biochem is best viewed as a specialized U.S. life-sciences company with a defensible technology niche, a global product footprint, and a recent history of strategic and listing-related changes that are material for equity investors. ([ir.enzo.com](https://ir.enzo.com/news-events/press-releases/detail/342/enzo-biochem-reports-third-quarter-fiscal-year-2025-results?utm_source=openai))
